Drug Type Trispecific T-cell engager (TriTE) |
Synonyms Trispecific antibody (CD3xCD28xHER2) - Sanofi, SAR 443216, SAR-443216 |
Target |
Mechanism CD28 inhibitors(T-cell-specific surface glycoprotein CD28 inhibitors), CD3 inhibitors(T cell surface glycoprotein CD3 inhibitors), HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
HER2 Positive Solid Tumors | Phase 1 | CN | 10 Jan 2024 | |
HER2 Positive Solid Tumors | Phase 1 | CN | 10 Jan 2024 | |
HER2 Positive Solid Tumors | Phase 1 | CN | 10 Jan 2024 | |
Breast Cancer | Phase 1 | US | 16 Aug 2021 | |
Breast Cancer | Phase 1 | BE | 16 Aug 2021 | |
Breast Cancer | Phase 1 | FR | 16 Aug 2021 | |
Breast Cancer | Phase 1 | KR | 16 Aug 2021 | |
Breast Cancer | Phase 1 | ES | 16 Aug 2021 | |
Breast Cancer | Phase 1 | TW | 16 Aug 2021 | |
Lung Cancer | Phase 1 | US | 16 Aug 2021 |